Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
The Combination of ISA101b and Libtayo® Shows Promising Results in Patients Whose Head and Neck Cancer Progressed on Anti-PD1 Therapy
ISA Pharmaceuticals B.V., a clinical-stage biotechnology company developing immunotherapies to treat cancers and serious infectious […]
ISA Pharmaceuticals to Present First Clinical Trial Data of ISA101b and Libtayo® in Head and Neck Cancer
ISA Pharmaceuticals, a clinical-stage biotechnology company developing immunotherapies to treat cancers and serious infectious diseases, […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more